EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

ViGenCell Inc. (308080) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of ViGenCell Inc. KRW 1,154, price KRW 5,720, upside -79.8%, quality 32 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR

VI Thin data Sep 24, 2026

ViGenCell Inc.

308080 · KQ

Weakest SetupStrongly overvalued and low quality.

!Fair value 1,154 KRW · Strongly overvalued (−80%)
!Quality 32/100
!Weak Growth (revenue YoY −91.9 %/yr)
!Low debt · negative free cash flow
!Trails peers (2/7)
!Narrow moat 5/100
!Evidence only low, so the estimate is less certain
Watch ViGenCell Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

30,500 KRW 2,345 KRW Fair Value 1,154 KRW Aug 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 2,345 KRW – 30,500 KRW · fair‑value band 761.31 KRW – 1,442 KRW · the 5,720 KRW price screens above the 1,154 KRW fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow ViGenCell in your weekly email

Every Wednesday you see whether ViGenCell is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ViGenCell Inc. provides immune cell therapy in South Korea.

Show more

ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic universal T cell gene therapy comprising VR-CAR and VR-GDT for hepatoma and leukemia indications. The company was founded in 2013 and is based in Seoul, South Korea.

Stock analysis

ViGenCell Inc. (308080) currently trades at 5,720 KRW, while our model-based Fair Value estimate is 1,154 KRW, implying the stock looks roughly 395.8% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 761.31 KRW (bear) to 1,442 KRW (bull), the price of 5,720 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

ViGenCell Inc. reported revenue of 22.7M KRW in FY2025 versus 0 KRW in FY2020. Reported net income was −16.3B KRW in FY2025.

Key figures

Market cap 117B KRW (≈ $81.9M) · Return on equity −20.2% · Return on assets (EBIT) −21.7% · Operating margin −4,862% · Free cash flow −14.6B KRW · Net debt 3.5B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).

What moves the price

The share trades about 64% below its 52-week high and 85% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −80%, 308080 screens richer than that median.

Fair Value models

Bear 761.31 KRW Fair Value 1,154 KRW Bull 1,442 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 1,066 KRW 1,429 KRW 2,133 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 1,066 KRW 1,429 KRW 2,133 KRW 54

Open the full fair value analysis →

Notify me when 308080 reaches fair value

Put 308080 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 32/100

Of which business quality 34 · Market factors (momentum, volatility) 37

Profitability 0
Margins and returns on capital today
Quality Growth 37
Are margins and returns improving?
Cashflow 8
Earnings quality: real cash, not paper profit
Fin. Strength 72
Balance sheet, leverage, solvency risk
Investment 67
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 51
Price trend over the last 3–12 months (market factor)
52W Momentum 55
Distance to the 52-week high (market factor)
Net Issuance 38
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
Revenue growth 1 year
−91.9%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

308080 screens 396% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare ViGenCell Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 34 · Below median
Fair Value upside −80% · Bottom 25%
Profitability
Return on assets −12% · Below median
Growth and dividend
Revenue growth 0% · Above median
Balance sheet
Debt / equity 0.17× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/S (TTM) 0.29× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)92 · sector 97
DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $514.99 $566.49 +10%
Regeneron Pharmaceuticals, Inc REGN $803.90 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.24 A$197.16 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ViGenCell Inc. · Fair Value
1,154 KRW −396%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "ViGenCell Inc. Fair Value". https://www.fairvalue-calculator.com/stock/308080

Frequently asked questions

Is ViGenCell Inc. (308080) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1,154 KRW versus a price of 5,720 KRW, about −80% upside (overvalued).
What is the fair value of 308080?
Our model-based fair value for ViGenCell Inc. is 1,154 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 5,720 KRW.
What is the quality score of 308080?
ViGenCell Inc. has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ViGenCell Inc. (308080)?
Our model-based price target is the fair value of 1,154 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 761.31 KRW, optimistic scenario 1,442 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the ViGenCell Inc. stock forecast for 2026?
Our models put fair value at 1,154 KRW, about −80% upside versus a price of 5,720 KRW (overvalued). Cautious scenario 761.31 KRW, optimistic scenario 1,442 KRW. The calculation is refreshed regularly with new filings.
What is the intrinsic value of ViGenCell Inc. (308080)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ViGenCell Inc. it is 1,154 KRW per share (as of Sep 24, 2026), against a price of 5,720 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is ViGenCell Inc. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 308080 trades above its calculated fair value: price 5,720 KRW, fair value 1,154 KRW, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 308080?
No. The price is what the market pays today (5,720 KRW); the fair value is what the company's own numbers justify (1,154 KRW). For ViGenCell Inc. the two are 4,567 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is ViGenCell Inc. worth?
The market values ViGenCell Inc. at about 117B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 5,720 KRW; our models calculate a fair value of 1,154 KRW per share.
What do the bullish and bearish scenarios say about 308080?
Our models span a range for ViGenCell Inc.: cautious scenario 761.31 KRW, base 1,154 KRW, optimistic 1,442 KRW per share (as of Sep 24, 2026, price 5,720 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ViGenCell Inc. (308080)?
Balance-sheet figures for ViGenCell Inc. (as of Sep 24, 2026): return on equity −20.2%, debt of 0.17 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is 308080 from its 52-week high?
ViGenCell Inc. trades at 5,720 KRW, about 64% below its 52-week high of 15,800 KRW and 85% above the low of 3,090 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 1,154 KRW is for.
Which stocks are comparable to ViGenCell Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ViGenCell Inc. stock attractive at the current price?
The data as of Sep 24, 2026: price 5,720 KRW, calculated fair value 1,154 KRW (−80%), Quality Score 32/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 308080 calculated?
We run ViGenCell Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,154 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. ViGenCell Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ViGenCell Inc. (308080)?
The closing price on Sep 23, 2026 was 5,720 KRW. Our model-based fair value is 1,154 KRW, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ViGenCell Inc. right now?
The price sits above even our optimistic bull case (1,442 KRW). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (761.31 KRW to 1,442 KRW) leaves room in how you read the outcome.

Key figures of ViGenCell Inc.

How large is the market capitalisation of ViGenCell Inc. (308080)?
The market capitalisation of ViGenCell Inc. is 117B KRW (≈ $81.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the return on equity of ViGenCell Inc. (308080)?
The return on equity (ROE) of ViGenCell Inc. is −20.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ViGenCell Inc. (308080)?
On an EBIT basis the return on assets of ViGenCell Inc. is −21.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ViGenCell Inc. (308080)?
The operating margin of ViGenCell Inc. is −4,862% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does ViGenCell Inc. (308080) generate?
The free cash flow of ViGenCell Inc. is −14.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does ViGenCell Inc. (308080) carry?
The net debt of ViGenCell Inc. is 3.5B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch ViGenCell Inc. in the live analysis

One click puts ViGenCell Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.